Curis Inc (CRIS)

$15.22

-0.73

(-4.58%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Curis Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.83M → 2.69M (in $), with an average decrease of 4.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -12.18M → -11.78M (in $), with an average increase of 3.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 63.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 338.2%

Performance

  • $14.63
    $16.50
    $15.22
    downward going graph

    3.88%

    Downside

    Day's Volatility :11.33%

    Upside

    7.76%

    downward going graph
  • $3.80
    $19.60
    $15.22
    downward going graph

    75.03%

    Downside

    52 Weeks Volatility :80.61%

    Upside

    22.35%

    downward going graph

Returns

PeriodCuris IncSector (Health Care)Index (Russel 2000)
3 Months
30.31%
-0.7%
0.0%
6 Months
230.23%
6.6%
0.0%
1 Year
-17.07%
3.7%
-1.5%
3 Years
-92.26%
14.0%
-21.8%

Highlights

Market Capitalization
90.0M
Book Value
$3.34
Earnings Per Share (EPS)
-8.96
PEG Ratio
0.0
Wall Street Target Price
21.75
Profit Margin
0.0%
Operating Margin TTM
-452.49%
Return On Assets TTM
-32.46%
Return On Equity TTM
-143.19%
Revenue TTM
10.0M
Revenue Per Share TTM
1.89
Quarterly Revenue Growth YOY
-6.6000000000000005%
Gross Profit TTM
-33.4M
EBITDA
-48.1M
Diluted Eps TTM
-8.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.2
EPS Estimate Next Year
-5.12
EPS Estimate Current Quarter
-2.11
EPS Estimate Next Quarter
-2.09

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Curis Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 42.9%

Current $15.22
Target $21.75

Company Financials

FY18Y/Y Change
Revenue
10.4M
↑ 5.35%
Net Income
-32.6M
↓ 38.9%
Net Profit Margin
-312.38%
↑ 226.28%
FY19Y/Y Change
Revenue
10.0M
↓ 4.07%
Net Income
-36.8M
↑ 12.98%
Net Profit Margin
-367.89%
↓ 55.51%
FY20Y/Y Change
Revenue
10.8M
↑ 8.31%
Net Income
-34.9M
↓ 5.22%
Net Profit Margin
-321.93%
↑ 45.96%
FY21Y/Y Change
Revenue
10.6M
↓ 1.72%
Net Income
-50.6M
↑ 45.18%
Net Profit Margin
-475.54%
↓ 153.61%
FY22Y/Y Change
Revenue
10.2M
↓ 4.57%
Net Income
-60.3M
↑ 19.12%
Net Profit Margin
-593.62%
↓ 118.08%
FY23Y/Y Change
Revenue
10.0M
↓ 1.37%
Net Income
-47.4M
↓ 21.4%
Net Profit Margin
-473.04%
↑ 120.58%
Q3 FY22Q/Q Change
Revenue
2.8M
↑ 18.05%
Net Income
-14.0M
↓ 16.87%
Net Profit Margin
-494.94%
↑ 207.9%
Q4 FY22Q/Q Change
Revenue
2.9M
↑ 2.19%
Net Income
-12.4M
↓ 11.04%
Net Profit Margin
-430.83%
↑ 64.11%
Q1 FY23Q/Q Change
Revenue
2.3M
↓ 20.44%
Net Income
-11.5M
↓ 7.61%
Net Profit Margin
-500.26%
↓ 69.43%
Q2 FY23Q/Q Change
Revenue
2.2M
↓ 4.35%
Net Income
-12.0M
↑ 4.09%
Net Profit Margin
-544.42%
↓ 44.16%
Q3 FY23Q/Q Change
Revenue
2.8M
↑ 28.95%
Net Income
-12.2M
↑ 1.84%
Net Profit Margin
-429.97%
↑ 114.45%
Q4 FY23Q/Q Change
Revenue
2.7M
↓ 4.84%
Net Income
-11.8M
↓ 3.29%
Net Profit Margin
-436.94%
↓ 6.97%
FY18Y/Y Change
Total Assets
37.4M
↓ 49.37%
Total Liabilities
41.9M
↓ 15.95%
FY19Y/Y Change
Total Assets
35.1M
↓ 6.04%
Total Liabilities
69.0M
↑ 64.87%
FY20Y/Y Change
Total Assets
204.4M
↑ 482.1%
Total Liabilities
73.7M
↑ 6.77%
FY21Y/Y Change
Total Assets
162.3M
↓ 20.58%
Total Liabilities
71.6M
↓ 2.84%
FY22Y/Y Change
Total Assets
108.8M
↓ 32.93%
Total Liabilities
62.3M
↓ 12.99%
FY23Y/Y Change
Total Assets
77.3M
↓ 29.0%
Total Liabilities
57.6M
↓ 7.52%
Q3 FY22Q/Q Change
Total Assets
122.9M
↓ 4.64%
Total Liabilities
67.1M
↑ 0.48%
Q4 FY22Q/Q Change
Total Assets
108.8M
↓ 11.4%
Total Liabilities
62.3M
↓ 7.17%
Q1 FY23Q/Q Change
Total Assets
94.5M
↓ 13.14%
Total Liabilities
58.0M
↓ 6.97%
Q2 FY23Q/Q Change
Total Assets
84.3M
↓ 10.83%
Total Liabilities
58.1M
↑ 0.22%
Q3 FY23Q/Q Change
Total Assets
90.0M
↑ 6.72%
Total Liabilities
60.4M
↑ 3.96%
Q4 FY23Q/Q Change
Total Assets
77.3M
↓ 14.11%
Total Liabilities
57.6M
↓ 4.59%
FY18Y/Y Change
Operating Cash Flow
-30.1M
↓ 37.82%
Investing Cash Flow
21.4M
↓ 688.82%
Financing Cash Flow
-6.0M
↓ 109.28%
FY19Y/Y Change
Operating Cash Flow
-26.2M
↓ 12.84%
Investing Cash Flow
-4.5M
↓ 120.85%
Financing Cash Flow
23.3M
↓ 490.39%
FY20Y/Y Change
Operating Cash Flow
-25.7M
↓ 1.78%
Investing Cash Flow
-49.0M
↑ 1000.72%
Financing Cash Flow
188.8M
↑ 711.37%
FY21Y/Y Change
Operating Cash Flow
-37.6M
↑ 46.16%
Investing Cash Flow
-47.9M
↓ 2.35%
Financing Cash Flow
-4.2M
↓ 102.21%
FY22Y/Y Change
Operating Cash Flow
-54.3M
↑ 44.44%
Investing Cash Flow
33.0M
↓ 168.95%
Financing Cash Flow
867.0K
↓ 120.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.1M
↑ 8.16%
Investing Cash Flow
4.3M
↓ 84.82%
Financing Cash Flow
4.7M
↓ 714.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.3M
↓ 6.51%
Investing Cash Flow
3.5M
↓ 19.52%
Financing Cash Flow
-1.4M
↓ 129.77%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.2M
↓ 0.56%
Investing Cash Flow
26.2M
↑ 657.81%
Financing Cash Flow
-2.0M
↑ 44.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 35.5%
Investing Cash Flow
-3.2M
↓ 112.02%
Financing Cash Flow
-852.0K
↓ 57.53%

Technicals Summary

Sell

Neutral

Buy

Curis Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Curis Inc
Curis Inc
57.14%
230.23%
-17.07%
-92.26%
-54.94%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Curis Inc
Curis Inc
NA
NA
0.0
-6.2
-1.43
-0.32
NA
3.34
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Curis Inc
Curis Inc
Buy
$90.0M
-54.94%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Maverick Capital Ltd

    9.88%

  • Kingdon Capital Management LLC

    9.64%

  • M28 Capital Management LP

    7.16%

  • Vanguard Group Inc

    3.54%

  • Artal Group S A

    1.78%

  • Citigroup Inc

    1.56%

Corporate Announcements

  • Curis Inc Earnings

    Curis Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

Organization
Curis Inc
Employees
49
CEO
Mr. James E. Dentzer
Industry
Health Technology

Discover More

FAQs